Business Strategy for the Biotech Field

Strategic planning is the process of systematically determining the capacity for most medical institutions to achieve their own resources, capabilities, and profitability and to allocate capital resources (Campobasso, 2000). A business strategy, an integral part of strategic planning, can be seen as a result of medical institutions meeting their external environment. As competition in the industry intensifies, organizations must make decisions about the strategic choice of products and services to compete in unstable markets, business growth and strategy depending on the type of organization's strategic positioning It changes.

Life science and biotechnology accelerators are currently collaborating with 11 promising startups. Here, they are involved in their skills, business development, value proposition, protection strategy, long-term financing strategy, pitching training and so on. 91% of Accelerator startups have already raised their investment through an average of 5 million Danish kroner. Accelerace also has partnership with Draupnir Bio. DraupnirBio has recently undergone the development of promising cholesterol lowering drugs from the Novo Nordisk Foundation for 5 million Danish krone. Draupnir Bio is also a finalist of NOM (Scandinavian mentor network for entrepreneurial spirit) biotechnology entrepreneurial competition. In this interview, I met the CEO of Drupinir Bio.

An important step that biotechnology companies tend to overlook when selecting CROs is the need to define criteria for achieving outsourcing or collaboration strategy from scratch. If the strategy is not clear, you will miss opportunities between the CRO service (either as a CRO recommendation or in consultation with a clinical team within a biotechnology company) and services as necessary. Biotechnology companies actually require that corporate goals be achieved from human relations

If biotechnology companies are somehow uncertain about the success criteria to be adopted in considering clinical trial strategies, they must obtain advice from independent experts. Regardless of whether a biotechnology company has defined it as a time-cost-quality matrix success criterion, these standards must be reflected in the model underlying the CRO's selection. 1) As a functional service provider, CRO: CRO provides insurance for specific functions (ie medical documents) when there is a skill gap in a biotechnology company. The advantages of biotechnology companies are cost-effective and streamlined processes, and biotechnology companies pay only for the services they need and for the specific period they require.